Kineta (KA) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Corporate company logo of Kineta Inc (KA)

The EV/EBITDA valuation chart for Kineta, Inc. (KA) demonstrates the development of a business striving to expand its KVA12123 antibody portfolio through B2B deals. The current metric stands at , however, pricing power has been lost due to a capital shortage, which led to a halt in research. Despite the crisis, Kineta, Inc. maintains its status as an immuno-oncology innovator, relying on the value of its patents for combating resistant tumors.

KA Kineta Corp: Enterprise Value to EBITDA Ratio in the range 07/04/2022 - 11/10/2026

kinetabio.com - analytical breakdowns and key metrics (KA)

- current price and projected stock value:
Stock Price Kineta Bio|KA - Analyst Median Target
- market capitalization details:
Market Value Kineta Corp|KA - Real Price to Acquire Entire Company
- book value of equity indicators:
Net Assets per Single Share Kineta|KA - Company Net Assets|Market Cap to Net Assets Ratio kinetabio.com|KA - Company Total Assets
- debt level and financial liquidity data:
Debt to Equity Kineta, Inc.|KA - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Kineta|KA - Company Cumulative Debt|Debt to Book Value Kineta Corp|KA - Long-Term Indebtedness|Company Current Liabilities Kineta|Quick Ratio kinetabio.com
- business earnings and investment ratios data:
KA - Final Profit|Projected Future Earnings Kineta, Inc.|KA - Market Cap to Earnings|Future Price to Earnings Kineta, Inc.|KA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Kineta Corp|KA - Operating profit EBITDA|Earnings per share for the last twelve months Kineta|KA - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months kinetabio.com|KA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Kineta, Inc.
Initial company analysis:Kineta Bio (KA)
Original product of Kineta

The high potential for pricing power of Kineta, Inc. (KA) in immuno-oncology, driven by the uniqueness of the KVA12.1 antibody, necessitates a precise business valuation. The EV/EBITDA multiple, accounting for capital structure, compares the total enterprise value of the company, including net debt, with its operating profit before interest, taxes, depreciation, and amortization. This chart allows investors to determine the real value of assets by eliminating distortions caused by the issuer's tax burden and debt strategy.

Main competitors

EV/EBITDA Multiple IBRX (ImmunityBio Corp)|Total Company Value to Operating Income Before Depreciation Ratio Immunocore Corp (IMCR)|JANX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|arcusbio.com (RCUS) - Enterprise Value to EBITDA Ratio|Zymeworks (ZYME) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Tango Therapeutics Inc|Enterprise Value to EBITDA Ratio IOVA|EV/EBITDA Multiple Immatics Biotechnologies|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|compasstherapeutics.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Replimune REPL|Lyell (LYEL) - Company Value to EBITDA|IPHA: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Pyxis Oncology, Inc. (PYXS)|CGEN (cgen.com) - Enterprise Value to EBITDA Ratio|IOBT: Enterprise Value to Operating Income Before Depreciation Ratio|STRO (Sutro Biopharma) - EV/EBITDA Multiple|INKT: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple HOWL|IMMX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ALX Oncology ALXO|Business Value to Operating Income Before Depreciation CUE|PDS Biotechnology Corp - EV/EBITDA Multiple|SONN - EV/EBITDA Multiple|MAIA Biotechnology Inc (MAIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LIMN (Liminatus)|Enterprise Value to EBITDA Ratio LVTX|Company Value to EBITDA nextcure.com NXTC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Leap Therapeutics, Inc. (LPTX)|EV/EBITDA Multiple intensitytherapeutics.com (INTS)|EV/EBITDA Multiple SNSE (Sensei Biotherapeutics, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Theriva Corp (TOVX)|GRTS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI (neximmune.com) - Enterprise Value to Operating Income Before Depreciation|TSBX: EV/EBITDA Multiple|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to EBITDA Ratio HARP